SC
CRSP icon

Saturna Capital’s CRISPR Therapeutics CRSP Stock Holding History

Saturna Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,779
Closed -$459K – 159
2024
Q3 		$459K Hold
9,779
– – 0.01% 127
2024
Q2 		$528K Sell
9,779
-1,151
-11% -$66.6K 0.01% 124
2024
Q1 		$745K Hold
10,930
– – 0.01% 121
2023
Q4 		$684K Buy
+10,930
New +$604K 0.01% 121
2023
Q3 		– Sell
-3,733
Closed -$210K – 175
2023
Q2 		$210K Buy
+3,733
New +$212K ﹤0.01% 160
2021
Q4 		– Sell
-1,880
Closed -$210K – 175
2021
Q3 		$210K Buy
1,880
+100
+6% +$12.6K ﹤0.01% 168
2021
Q2 		$288K Buy
+1,780
New +$216K 0.01% 156
2021
Q1 		– Sell
-13,000
Closed -$1.99M – 167
2020
Q4 		$1.99M Sell
13,000
-1,200
-8% -$142K 0.05% 86
2020
Q3 		$1.19M Hold
14,200
– – 0.03% 94
2020
Q2 		$1.04M Buy
+14,200
New +$830K 0.03% 100
2020
Q1 		– Sell
-3,400
Closed -$207K – 180
2019
Q4 		$207K Buy
+3,400
New +$186K 0.01% 184

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Saturna Capital's CRSP Position: Q4 2024 in Review

Saturna Capital sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 9,779 shares — an estimated $459K sold.

Saturna Capital first reported a position in CRSP in Q4 2019 and held it in 11 quarters. The position peaked at $1.99M in Q4 2020. 405 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • Saturna Capital reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Saturna Capital sold 9,779 CRISPR Therapeutics shares in Q4 2024, an estimated $459K.
  • Saturna Capital first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 11 quarters.
  • Saturna Capital's CRISPR Therapeutics position peaked at $1.99M in Q4 2020.
  • 405 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Saturna Capital's 13F filing for Q4 2024, filed 7 Feb 2025.